MacroGenics Q4 2023 Earnings Report
Key Takeaways
MacroGenics reported a net loss of $9.1 million for the year ended December 31, 2023, compared to a net loss of $119.8 million for the year ended December 31, 2022. The company's cash, cash equivalents, and marketable securities balance was $229.8 million as of December 31, 2023. They anticipate the cash runway extended into 2026.
Preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024
Initiated Phase 1 study of MGC026, MacroGenics' first topoisomerase I inhibitor-based ADC
Preclinical data on two topoisomerase I inhibitor-based ADC product candidates, MGC026 and MGC028, to be presented in posters at AACR
Completed enrollment of 177 patients in the TAMARACK Phase 2 study of vobra duo in November 2023, exceeding the study design goal of 100 participants.
MacroGenics
MacroGenics
MacroGenics Revenue by Segment
Forward Guidance
MacroGenics anticipates that its cash, cash equivalents and marketable securities balance of $229.8 million as of December 31, 2023, in addition to projected and anticipated future payments from partners and product revenues should extend its cash runway into 2026.